Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05070845 · ClinicalTrials.gov registry record · Phase 2
Safety and Efficacy Study of PF-06835375 in Primary Immune Thrombocytopenia
A Phase 2 study of Primary Immune Thrombocytopenia, sponsored by Pfizer.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 61
- Enrollment target
- 20
- Study locations
NCT05070845 is a Phase 2 study of Primary Immune Thrombocytopenia that is actively recruiting participants, run by Pfizer. The registered enrollment target is 61 participants, below the 124-participant average among 4 other Primary Immune Thrombocytopenia trials with a reported enrollment target (51% lower). The trial reports 20 study locations across 11 states.
The verdict
NCT05070845, a Phase 2 study of Primary Immune Thrombocytopenia, is actively recruiting participants, sponsored by Pfizer.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 61 participants
- Enrollment target
- 20
- Study locations
Study Summary
This is a Phase 2, open-label, multicenter, multiple subcutaneous injection, safety and efficacy study of PF-06835375 in adult participants with primary immune thrombocytopenia (ITP). This study will focus on participants with persistent (\>3 months and ≤12 months), or chronic (\>12 months) ITP
Conditions Studied
Interventions
- BIOLOGICAL PF-06835375
Study Locations (20)
Other
- Fakultni nemocnice Hradec Kralove - Hradec Králové
- Vseobecna fakultni nemocnice v Praze - Prague
- Semmelweis University - Budapest
- Petz Aladár Egyetemi Oktató Kórház - Győr
- Komárom-Esztergom Vármegyei Szent Borbála Kórház - Tatabánya
- InterHem - Bialystok
- Klinika Hematologii i Transplantologii Uniwersyteckie Centrum Kliniczne - Gdansk
- Pratia Onkologia Katowice - Katowice
New South Wales
- South West Radiology - Liverpool
- Slade Pharmacy - Mount Kuring-Gai
- Calvary Mater Newcastle - Waratah
North Carolina
- East Carolina University - Greenville
South Australia
- ICON Cancer Centre - Kurralta Park - Kurralta Park
Victoria
- The Alfred Hospital - Melbourne
Western Australia
- Royal Perth Hospital - Perth
Ontario
- Unity Health Toronto, St. Michael's Hospital - Toronto
Quebec
- McGill University Health Centre - Montreal
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 61 participants |
| Start Date | 2022-02-02 |
| Est. Completion | 2027-10-01 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05070845
The ClinicalTrials.gov registry entry for NCT05070845 describes a study currently listed as recruiting, categorized as Phase 2. The registered enrollment target is 61 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 124-participant average among 4 other Primary Immune Thrombocytopenia trials with a reported enrollment target (51% lower). The listed sponsor is Pfizer, which has 1,845 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Primary Immune Thrombocytopenia appearing as the primary indexed condition, and to 1 intervention - of which PF-06835375 is the first listed.
NCT05070845 reports 20 study locations spanning 11 distinct geographic areas - top geographies include Other, New South Wales, North Carolina.
Frequently Asked Questions
What is clinical trial NCT05070845 about?
NCT05070845 is a clinical study titled "Safety and Efficacy Study of PF-06835375 in Primary Immune Thrombocytopenia". This is a Phase 2, open-label, multicenter, multiple subcutaneous injection, safety and efficacy study of PF-06835375 in adult participants with primary immune thrombocytopenia (ITP). This study will focus on participants with persistent (\>3 months and ≤12 months), or chronic (\>12 months) ITP
What is the current status of trial NCT05070845?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 61 participants. The study started on 2022-02-02. Estimated completion is 2027-10-01.
What conditions does trial NCT05070845 study?
This clinical trial studies the following conditions: Primary Immune Thrombocytopenia.
What interventions are being tested in trial NCT05070845?
The interventions under investigation include: PF-06835375 (BIOLOGICAL).
Who is sponsoring clinical trial NCT05070845?
This trial is sponsored by Pfizer, which has 1,845 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05070845 being conducted?
This trial has 20 study locations across North Carolina, New South Wales, South Australia, Victoria, Western Australia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Primary Immune Thrombocytopenia
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Study of TAK-079 in Adults With Persistent/Chronic Primary Immune Thrombocytopenia
COMPLETED · Phase 2
-
A Phase 3 Study to Evaluate the Safety and Efficacy of Efgartigimod PH20 Subcutaneous in Adult Patients With Primary Immune Thrombocytopenia
ACTIVE NOT RECRUITING · Phase 3
-
A Study of Efficacy and Safety of Ianalumab Versus Placebo in Addition to Eltrombopag in Primary Immune Thrombocytopenia Patients Who Failed Steroids
ACTIVE NOT RECRUITING · Phase 3
-
A Study to Assess the Efficacy and Safety of Efgartigimod in Adult Patients With Primary Immune Thrombocytopenia (ITP).
COMPLETED · Phase 3
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.